OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery
Víctor Lago(Universidad Cardenal Herrera CEU), Santiago Domingo(Hospital Universitari i Politècnic La Fe), Christina Fotopoulou(Ovarian Cancer Action), Natasha Rinne(Hospital Universitario Virgen de la Arrixaca), Martina Aida Ángeles(Hospital Sant Joan de Déu Barcelona), Mustafa Zelal Muallem(Humboldt-Universität zu Berlin), Giovanni Scambia(Agostino Gemelli University Polyclinic), Antonio Gil‐Moreno(Universitat Autònoma de Barcelona), Virginia Vargiu(Agostino Gemelli University Polyclinic), Mathilde Del(Institut Claudius Regaud), Lucas Minig, José Luis Sánchez Iglesias, Lourdes Sala Climent(Humboldt-Universität zu Berlin), Alejandra Martínez(Institut universitaire du cancer de Toulouse Oncopole), Gwénaël Ferron(Inserm), Pablo Padilla-Iserte(Hospital Universitari i Politècnic La Fe), Luis Chiva(Clinica Universidad de Navarra), Manel Montesinos, Luisa Kluge(Humboldt-Universität zu Berlin), Luis Matute, Serena Cappucio(Università Cattolica del Sacro Cuore), A. Tejerizo-García(Research Institute Hospital 12 de Octubre), Blanca Segarra-Vidal(Hospital Universitari i Politècnic La Fe), Enrique Chacón(Clinica Universidad de Navarra), Pedro Antonio Cáscales-Campos(Hospital Universitario Virgen de la Arrixaca), Marta Gurrea, Myriam García Segovia, Israel Manzanedo(Universidad Rey Juan Carlos), Anna Fagotti, David Hervás(Universitat Politècnica de València)
Cited by 12
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k
<scp>FIGO</scp> staging of endometrial cancer: 2023
|International Journal of Gynecology & Obstetrics|2023|926
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta‐analysis
|Ultrasound in Obstetrics and Gynecology|2017|299